Astra goes pivotal with CTLA-4
Liver toxicity notwithstanding, volrustomig will start a phase 3 lung cancer study versus Keytruda imminently.
Liver toxicity notwithstanding, volrustomig will start a phase 3 lung cancer study versus Keytruda imminently.
However, endometrial cancer remains a small use, and Jemperli has other ways to make a bigger splash.
Regeneron’s fianlimab could be biopharma’s most potent Lag3 project, and has shown activity in a new melanoma setting
The limited activity of Reblozyl in myelodysplastic syndromes patients without ringed sideroblasts could help Geron.